There are not enough resources in health care systems around the world to fund all technically feasible and potentially beneficial health care interventions. Difficult choices have to be made, and economic evaluation offers a systematic and transparent process for informing such choices. A key component of economic evaluation is how to value the benefits of health care in a way that permits comparison between health care interventions, such as through costs per quality-adjusted life years (QALY). Measuring and Valuing Health Benefits for Economic Evaluation examines the measurement and valuation of health benefits, reviews the explosion of theoretical and empirical work in the field, and explores an area of research that continues to be a major source of debate. It addresses the key questions in the field including: the definition of health, the techniques of valuation, who should provide the values, techniques for modelling health state values, the appropriateness of tools in children and vulnerable groups, cross cultural issues, and the problem of choosing the right instrument. This new edition contains updated empirical examples and practical applications, which help to clarify the readers understanding of real world contexts. It features a glossary containing the common terms used by practitioners, and has been updated to cover new measures of health and wellbeing, such as ICECAP, ASCOT and AQOL. It takes into account new research into the social weighting of a QALY, the rising use of ordinal valuation techniques, use of the internet to collect data, and the use of health state utility values in cost effectiveness models. This is an ideal resource for anyone wishing to gain a specialised understanding of health benefit measurement in economic evaluation, especially those working in the fields of health economics, public sector economics, pharmacoeconomics, health services research, public health, and quality of life research.

To order please visit https://onlineacademiccommunity.uvic.ca/press/books/ordering/

With limited resources and funding, it is impossible to invest in all potentially beneficial health care interventions. Choices have to be made, and this practical guide allows the reader to measure and value the benefits of interventions, a key component of economic evaluation, which then permits comparisons between interventions.

This title was first published in 2002. Most of those working in health services are aware of scarcity and the need for choice, and many also know that health sector choices in the future may be made on a "cost per quality-adjusted-life-year" (QALY) basis. This volume explains health service choice, focusing in particular on the QALY success story, and the merits and drawbacks of this measure are explained. On the basis of some of the problems identified, a new QALY-based approach to resource allocation is developed, and other methods of priority setting are explained, ranging from heart surgery to Alzheimer's Disease. The author explains the problems of health sector choice from first principles, in an approach that should be particularly useful to healthcare professionals, pharmaceutical industry managers, and students of economics.

In this book the authors explore the state of the art on efficiency measurement in health systems and international experts offer insights into the pitfalls and potential associated with various measurement techniques. The authors show that: - The core idea of efficiency is easy to understand in principle - maximizing valued outputs relative to inputs, but is often difficult to make operational in real-life situations - There have been numerous advances in data collection and availability, as well as innovative methodological approaches that give valuable insights into how efficiently health care is delivered - Our simple analytical framework can facilitate the development and interpretation of efficiency indicators.

As expenditure on health care has increasingly become an area of public debate and concern, public and private health care decision-makers have called for more rigorous use of cost-benefit and cost-effectiveness analysis to guide spending. Concerns have arisen, however, about the overall quality of such analyses. This book discusses and evaluates best-practice methods of conducting cost-benefit and cost-effectiveness studies of pharmaceuticals and other medical technologies. It encompasses a wide variety of topics, ranging from measuring cost and effectiveness to discounting to the use of dynamic modelling of cost-effectiveness. The book also includes conceptual and practical aspects of cost-effectiveness analysis by researchers who have conducted applied research in these areas. Rarely does the book provide a singular solution to a measurement problem; rather, the reader is directed to choices among alternative approaches and an analysis of the advantages and disadvantages of each.